Stock Events

Stock Events

Novo Nordisk 

0
20835
+€0.00+0% 00:00 Today

Statistics

Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Dividends

0%Dividend Yield
Aug 2026
€0.50
Mar 2026
€1.06
Aug 2025
€0.50
Apr 2025
€1.06
Aug 2024
€0.47
10Y Growth
6.66%
5Y Growth
20.02%
3Y Growth
18.13%
1Y Growth
0.28%

Earnings

Nov 4Expected
Q1 2026
Q2 2026
Next
0.64
0.72
0.79
0.87
Expected EPS
0.642266786253456
Actual EPS
N/A

Financials

33.14%Profit Margin
Profitable
2020
2021
2022
2023
2024
2025
41.41BRevenue
13.72BNet Income

Analyst Ratings

$30.35Average Price Target
The highest estimate is ⁦30.35⁩.
From 2 ratings within the last 6 months. This is not an investment recommendation.
Buy
0%
Hold
50%
Sell
50%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow NOVC.MU. It's not an investment recommendation.
Microsoft
3710
MSFT
NVIDIA
3536
NVDA
Alphabet
2874
GOOGL
Amazon
2858
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Sanofi
SNY
Mkt Cap106.24B
Sanofi competes directly with Novo Nordisk in the diabetes and insulin markets, offering similar products and therapies.
Lilly(Eli) &
LLY
Mkt Cap1.26T
Eli Lilly is a major competitor in the diabetes care market, particularly in insulin and GLP-1 receptor agonists, directly competing with Novo Nordisk's portfolio.
Astrazeneca
AZN
Mkt Cap289.48B
AstraZeneca competes in the diabetes sector with its range of type 2 diabetes medications, posing competition to Novo Nordisk's diabetes care products.
Merck
MRK
Mkt Cap368.89B
Merck is a competitor in the diabetes market with its drug Januvia among others, competing with Novo Nordisk's diabetes management products.
Bristol-Myers Squibb
BMY
Mkt Cap127.71B
Bristol Myers Squibb competes in the area of diabetes and cardiovascular diseases, areas where Novo Nordisk also has a significant presence.
Pfizer
PFE
Mkt Cap173.95B
Pfizer competes with Novo Nordisk in various therapeutic areas, including chronic diseases, though not as directly in diabetes.
Novartis
NVS
Mkt Cap303.67B
Novartis competes across a broad range of therapeutic areas including cardiovascular, which overlaps with Novo Nordisk's interests.
Johnson & Johnson
JNJ
Mkt Cap657.68B
Johnson & Johnson, through its pharmaceutical division Janssen, competes in several areas including diabetes care.
Abbott Laboratories
ABT
Mkt Cap183.77B
Abbott Laboratories competes with Novo Nordisk in the broader healthcare market, including diabetes management through its glucose monitoring devices.
Thermo Fisher Scientific
TMO
Mkt Cap257.71B
Thermo Fisher Scientific competes indirectly by providing instruments and reagents for diabetes research, affecting the market landscape.

About

With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the world's leading provider of diabetes care products. Based in Denmark, the company manufactures and markets a variety of human and modern insulins for patients with diabetes, as well as injectable and oral GLP-1 therapies, across its obesity and diabetes care segment. Novo also has a rare disease segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Show More
CEO
Maziar Mike Doustdar
Employees
69500
Country
Denmark
ISIN
DK0060534915
WKN
000A3EU6F

Listings

WA
PL
NVO.WA
MX
MX
NOVOBN.MX
LSE
GB
0TDD.LSE
MU
DE
NOVA.MU

0 Comments

Share your thoughts

FAQs

What is Novo Nordisk stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Boerse Muenchen exchange Novo Nordisk stocks are traded under the ticker NOVC.MU.
When is the next Novo Nordisk earnings date?▼
Novo Nordisk is going to release the next earnings report on November 4, 2026.
What were Novo Nordisk earnings last quarter?▼
NOVC.MU earnings for the last quarter are 0.82 EUR per share, whereas the estimation was 0.66 EUR resulting in a +22.86% surprise. The estimated earnings for the next quarter are N/A EUR per share.
What is Novo Nordisk revenue for the last year?▼
Novo Nordisk revenue for the last year amounts to 41.41B EUR.
What is Novo Nordisk net income for the last year?▼
NOVC.MU net income for the last year is 13.72B EUR.
Does Novo Nordisk pay dividends?▼
Yes, NOVC.MU dividends are paid semi-annual. The last dividend per share was 0.5 . As of today, Dividend Yield (FWD)% is 0%.
How many employees does Novo Nordisk have?▼
As of November 3, 2026, the company has 69,500 employees.
In which sector is Novo Nordisk located?▼
Novo Nordisk operates in the Health & Wellness sector.
When did Novo Nordisk complete a stock split?▼
The last stock split for Novo Nordisk was on September 13, 2023 with a ratio of 2:1.
Where is Novo Nordisk headquartered?▼
Novo Nordisk is headquartered in Bagsvaerd, Denmark.